Science Explorer Back to mapMap

Most cited papers in Lung Cancer Treatments and Mutations

Lung Cancer Treatments and Mutations

What are the most cited papers in Lung Cancer Treatments and Mutations?

The most cited paper in Lung Cancer Treatments and Mutations is "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)" (E. A. Eisenhauer, P. Therasse, Jan Bogaerts et al., 2008), with 30,125 citations. Next come "The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology" (16,252) and "New Guidelines to Evaluate the Response to Treatment in Solid Tumors" (15,773).

Showing 50 of 99 papers. Every paper with more than 2,207 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. A. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer 27 Dec 2008 30,125
2 The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology N.K. Aaronson, Sam Hjelmeland Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute 3 Mar 1993 16,252
3 New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute 2 Feb 2000 15,773
4 Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine 19 May 2004 11,595
5 Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening The National Lung Screening Trial Research Team · New England Journal of Medicine Open access 29 Jun 2011 11,266
6 The Cancer Genome Atlas Pan-Cancer analysis project John N. Weinstein, Eric A Collisson, Gordon Brent Mills et al. · Nature Genetics Open access 26 Sep 2013 9,847
7 EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi Antero Janne, Jeffrey C. Lee et al. · Science 3 May 2004 9,471
8 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access 31 May 2015 8,632
9 Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine Open access 19 Aug 2009 8,331
10 Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi et al. · Science Open access 12 Mar 2015 8,049
11 Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi et al. · New England Journal of Medicine Open access 16 Apr 2018 6,764
12 The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians Open access 17 Jan 2017 6,689
13 A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments] NL Harris, ES Jaffe, H Stein et al. · Blood Open access Sep 1994 6,356
14 Cancer treatment and survivorship statistics, 2016 Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians Open access 2 Jun 2016 6,175
15 Comprehensive molecular profiling of lung adenocarcinoma Eric A. Collisson et al. · Nature Open access310 authors 8 Jul 2014 5,968
16 Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine Open access 13 Dec 2006 5,802
17 Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo et al. · New England Journal of Medicine 23 Jun 2010 5,607
18 Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access 30 Jan 2012 5,563
19 Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature 11 Jul 2007 5,494
20 Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova et al. · Cell Reports Open access 2017 5,483
21 Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine Open access 18 Nov 2017 5,475
22 Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine Open access 13 Jul 2005 5,471
23 A New Initiative on Precision Medicine Francis S. Collins, HAROLD E. VARMUS · New England Journal of Medicine Open access 30 Jan 2015 5,301
24 The biology and management of non-small cell lung cancer Roy S. Herbst, Daniel Morgensztern, CHRIS H. BOSHOFF · Nature 2018 5,116
25 Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David T. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine 10 Jan 2002 5,010
26 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma William David Travis et al. · Journal of Thoracic Oncology Open access 20 Jan 2011 4,890
27 The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer Peter Goldstraw et al. · Journal of Thoracic Oncology Open access152 authors 2016 4,749
28 Cancer drug resistance: an evolving paradigm Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley et al. · Nature reviews. Cancer Review 24 Sep 2013 4,739
29 Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Luca Richeldi et al. · New England Journal of Medicine Open access 18 May 2014 4,731
30 Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Scott Joseph Antonia et al. · New England Journal of Medicine Open access 8 Sep 2017 4,653
31 Revisions in the International System for Staging Lung Cancer Clifton F. Mountain · CHEST Journal Jun 1997 4,608
32 Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice Lee Kwak et al. · New England Journal of Medicine Open access 27 Oct 2010 4,517
33 MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science 26 Apr 2007 4,504
34 Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert M. Samstein et al. · Nature Genetics Open access 8 Jan 2019 4,458
35 Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells Wanjuan Yang, Jorge Soares, Patricia Greninger et al. · Nucleic Acids Research Open access 22 Nov 2012 4,422
36 EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib William J. Pao, Vincent A. Miller, Maureen Frances Zakowski et al. · Proceedings of the National Academy of Sciences Open access 25 Aug 2004 4,369
37 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Tetsuya Mitsudomi et al. · The Lancet Oncology 19 Dec 2009 4,130
38 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou et al. · The Lancet Oncology 25 Jul 2011 4,126
39 Comprehensive genomic characterization of squamous cell lung cancers Peter S. Hammerman et al. · Nature Open access339 authors 7 Sep 2012 4,071
40 High Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer Pepijn Brocken, Henricus F.M. van der Heijden, P.N.R. Dekhuijzen et al. · Respiration Open access 16 Apr 2013 4,004
41 EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Susumu S. Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine Open access 23 Feb 2005 3,981
42 Tumour heterogeneity and resistance to cancer therapies Ibiayi Dagogo‐Jack, Alice Tsang Shaw · Nature Reviews Clinical Oncology Review 8 Nov 2017 3,967
43 Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine Open access 4 Jun 2018 3,816
44 The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours Peter Goldstraw, John Crowley, Kari Chansky et al. · Journal of Thoracic Oncology Open access Aug 2007 3,691
45 Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial Harry J. de Koning et al. · New England Journal of Medicine Open access 29 Jan 2020 3,674
46 Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia Van Dam Sequist et al. · Science Translational Medicine Open access 23 Mar 2011 3,603
47 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Ahmet Zehir et al. · Nature Medicine Open access100 authors 8 May 2017 3,585
48 Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain William J. Pao, Vincent A. Miller, Katerina A. Politi et al. · PLoS Medicine Open access 17 Feb 2005 3,557
49 Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Bruce D. Cheson, Sandra J. Horning, Bertr Coiffier et al. · Journal of Clinical Oncology Apr 1999 3,495
50 Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access Jun 2013 3,429

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.